期刊文献+

RT-PCR检测SALL4基因在白血病中的表达 被引量:7

Detection of SALL4 mRNA expression in leukemia cells by RT-PCR
下载PDF
导出
摘要 目的:检测SALL4基因在白血病细胞中的表达情况。方法:运用RT-PCR技术对35例白血患者及10例正常对照的单个核细胞进行SALL4mRNA表达测定。结果:急性非淋巴细胞白血病(ANLL)患者中,SALL4mRNA表达率为83.3(15/18);慢性髓细胞白血病(CML)患者SALL4mRNA表达率为100(7/7);B-ALL患者中,SALL4mRNA表达率为100(6/6),T-ALL的SALL4mRNA表达率为0(0/4)。对照组10例的SALL4mRNA表达为阴性。ANLL、CML、B-ALL之间SALL4mRNA的表达率比较差异无统计学意义(P>0.05),前3组与T-ALL、对照组间SALL4mRNA的表达差异有统计学意义(P<0.01)。BCR-ABL融合基因与SALL4在ALL、CML组中的表达呈正相关性。结论:ANLL、CML、B-ALL的单个核细胞SALL4mRNA表达阳性,提示SALL4基因可能与白血病的发生相关;B-ALL与T-ALL间的SALL4基因表达差异有统计学意义,提示2者的发病机制可能不同。 Objective:To detect SALL4 mRNA expression in leukemia cells. Method:RT-PCR method was used for detecting SALL4 mRNA expression in the mononuclear cells of 35 patients with leukemia and 10 normal controis. Result:The positive rates of SALL4 mRNA expression were 83.3% (15 of 18) in patients with ANNL, 100% in patients (7/7) with CML,100% (6 of 6) in patients with B-ALL and 0 (0/4) in patients with T-ALL. Expression of SALL4 mRNA was negative in 10 normal controls. In the positive rates of SALL4 mRNA expression among ANLL, CML and B-ALL, the differences were not statistically significant ( P 〉0.05). In the expression rates of the previous three groups with T-ALL and normal controls respectively, the differences were statistically significant ( P 〈0.01). We found there was obvious relationship between the expression of BCR-ABL gene and SALL4 mRNA in the cases with CML or ALL by association analysis. Conclusion: Expression of SALL4 mRNA was positive in the mononuclear cells of the patients with ANLL, CML and B-ALL. The results suggested that SALL4 mRNA may be related to the genesis of leukemia. The significant difference between expression rates in cases with BALL and T-ALL indicates that there is variant pathogenesis between them.
出处 《临床血液学杂志》 CAS 2008年第6期600-602,共3页 Journal of Clinical Hematology
关键词 白血病 RT-PCR SALL4 MRNA Leukemia RT-PCR SALL4 mRNA
  • 相关文献

参考文献9

  • 1FRECER V, MIERTUS J, BOROZDIN W, et al. Molecular Modeling of c2h2 Zinc Finger Mutation of Putative Human Transcription Factor SALL4 [J].IEJMD, 2004,3 : 295-- 307.
  • 2ZHANG J,TAM W L,TONGG Q,et al. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of PouSfl[J]. Nat Cell Biol, 2006,8 : 1114-- 1123.
  • 3AL BARADIE R, YAMADA K, ST HILAIRE C, et al. Duane radial ray syndrome (Okihiro syndrome) maps to 20q13 and results from mutations in SALL4, a new member of the SAL family[J]. Am J Hum Genet,2002,71:1195--1199.
  • 4KOHLHASE J, HEINRICH M, SCHUBERT L, et al. Okihiro syndrome is caused by SALL4 mutations [J]. Hum Mol Genet,2002,11 :2979--2987.
  • 5BOEHM J, SUSTMANN C, WILHELM C, et al. SALL4 is directly activated by TCF/LEF in the canonical Wnt signaling pathway [J]. Biochem Biophys Res Commun, 2006,348 : 898-- 907.
  • 6MA Y,CUI W, YANG J, et al. SALL4, a novel oncogene,is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice[J]. Blood, 2006,8 :2726 -- 2735.
  • 7YANG JIANCHANG, LI CHAI, LIU FANG, et al. Bmi 1 is a target gene for SALL4 in hematopoieticand leukemic cells[J]. PNAS, 2007,19 : 10494 -- 10499.
  • 8陈凤花,王琳,胡丽华.原癌基因BMI-1的研究进展[J].临床血液学杂志(输血与检验),2007,20(4):189-191. 被引量:4
  • 9CUI W, KONG N R, MA Y, et al. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia[J]. Modern Pthology, 2006,19 : 1585-- 1592.

二级参考文献16

  • 1VONCKENJ W,NIESSEN H,NEUFELD B,et al.MAPKAP kinase3pK phosphorylates and regulates chromatin association of the Polycomb Group Protein BMI-1. Journal of Biological Chemistry . 2005
  • 2DUKERS D F,VAN GALENJC,GIROTHC,et al.Unique polycomb gene expression patternin Hodgkin‘s lymphoma and Hodgkin‘s lymphoma-derived cell lines. American Journal of Pathology . 2004
  • 3RAAPHORST F M,VERMEER M,FIERET E,et al.Site-specific expression of polycomb-group genes encoding the HPC-HPH/PRC1complex in clinically defined pri mary nodal and cutaneous large B-cell lym-phomas. American Journal of Pathology . 2004
  • 4MI HARA K,CHOWDHURY M,NAKAJU N,et al.BMI-1is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and prognosis of the patients. Blood . 2006
  • 5Kranc KR,Bamforth SD,Braganca J,et al.Transcriptional coactivatorCited2 induces Bmi1 and Mel18 and controls fibroblast proliferation viaInk4a/ARF. Molecular and Cellular Biology . 2003
  • 6Kevin S. Smith Sumit K. Chanda 5 Merel Lingbeek4 5 Douglas T. Ross David Botstein Maarten van Lohuizen4 and Michael L. Cleary img src.Bmi-1 Regulation of INK4A-ARF Is a Downstream Requirement for Transformation of Hematopoietic Progenitors by E2a-Pbx1. Molecular Cell . 2003
  • 7ITAHANAK,ZOUY,ITAHANAY,et al.Control of the replica-tive life span of human fibroblasts by p16and the polycomb protein Bmi-1. Molecular and Cellular Biology . 2003
  • 8Dimri G P,Martinez J L,Jacobs J J,et al.The Bmi-1oncogene induces telomerase activity and immortalizes humanmammary epithelial cells. Cancer Research . 2002
  • 9Ru Cao Yu-ichi Tsukada and Yi Zhang.Role of Bmi-1 and Ring1A in H2A Ubiquitylation and Hox Gene Silencing. Molecular Cell . 2005
  • 10Park I K,Qian D,Kiel M,et al.Bmi-1 is required for mai ntenance of adult self-rene wi ng hae matopoietic ste mcells. Nature . 2003

共引文献3

同被引文献86

  • 1丁丽萍.某院3443例消化系恶性肿瘤分类构成分析[J].中国医院统计,2005,12(4):376-377. 被引量:11
  • 2扶云碧,孙启鑫,孟凡义,谢军,周光飚.蛋白酶体抑制剂硼替佐米诱导髓系白血病细胞株 HL60凋亡的机制研究[J].中华医学杂志,2006,86(34):2413-2416. 被引量:14
  • 3宋卫亚,牟伟益,宋洁,张进,牛红卫.我市27563例住院恶性肿瘤调查[J].中国医院统计,2006,13(4):346-347. 被引量:9
  • 4陈万青,张思维,孔灵芝,李光琳,赵平.中国部分市县2003年恶性肿瘤死亡年度报告[J].中国肿瘤,2007,16(8):586-597. 被引量:21
  • 5Adams J.The development of proteasome inhibitors as anticancer drugs[J].Cancer Cell, 2004,5 ( 5 ) : 417-421.
  • 6Bavi P, Uddin S, Ahmed M, et al.Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma[J].Am J Pathol,2011,178 ( 5 ) :2109-2120.
  • 7Benevolo G, Larocca A, Gentile M, et al.The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with multiple myeloma who are responsive to salvage bortezomib-containing regimens[J].Cancer, 2011,117 ( 9 ) : 1884-1890.
  • 8Attar E C, De Angelo D J, Supko J G, et al.Phase I and pharmacokinetic study of bortezomib in combination with idarubicinand cytarabine in patients with acute myelogenous leukemia[J].Clin Cancer Res, 2008,14 ( 5 ) : 1446-1454.
  • 9Yang J, Chai L, Gao C, et al.SALL4 is a key regulator of survival and apoptosis in human leukemic cells[J].Blood, 2008,112 ( 3 ) : 805 -813.
  • 10Guzman M L, Swiderski C F, Howard D S, et al.Preferential induction of apoptosis for primary human leukemic stem cells[J].Proc Natl Acad Sei USA,2002,99 ( 25 ) : 16220-16225.

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部